Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl
10.1001/jamanetworkopen.2023.34540 · doi-reference
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
10.1016/s0140-6736(17)32812-x · doi-reference
A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults
10.1111/add.13363 · doi-reference
10.1176/appi.books.9780890425596
10.1176/appi.books.9780890425596 · doi-reference
Validation and performance of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) among adolescent primary care patients
10.1111/add.12767 · doi-reference
Screening adolescents for nicotine dependence: the Hooked On Nicotine Checklist
10.1016/s1054-139x(03)00531-7 · doi-reference
Validity of the CRAFFT substance abuse screening test among adolescent clinic patients
10.1001/archpedi.156.6.607 · doi-reference
Validity of brief screening instrument for adolescent tobacco, alcohol, and drug use
10.1542/peds.2013-2346 · doi-reference
Substance Use Screening, Brief Intervention, and Referral to Treatment
10.1542/peds.2016-1211 · doi-reference
Sensitivity and specificity of S2BI for identifying alcohol and cannabis use disorders among adolescents presenting for primary care
10.1080/08897077.2020.1803180 · doi-reference
“My life isn’t defined by substance use”: recovery perspectives among young adults with substance use disorder
10.1007/s11606-021-06934-y · doi-reference
Defining and operationalizing the phenomena of recovery: a working definition from the recovery science research collaborative
10.1080/16066359.2018.1515352 · doi-reference
Buprenorphine treatment duration and adherence among youth and subsequent health outcomes
10.1542/peds.2025-071147 · doi-reference
Transition to adulthood for youth with chronic conditions and special health care needs
10.1016/j.jadohealth.2020.02.006 · doi-reference
Developing harm reduction in the context of youth substance use: insights from a multi-site qualitative analysis of young people’s harm minimization strategies
10.1186/s12954-017-0180-z · doi-reference
Addressing adolescent substance use with a public health prevention framework: the case for harm reduction
10.1080/07853890.2022.2104922 · doi-reference
Anticipatory guidance to prevent adolescent overdoses
10.1542/peds.2023-065217 · doi-reference
Opioid-overdose laws association with opioid use and overdose mortality
10.1016/j.addbeh.2018.03.014 · doi-reference
Naloxone expansion is not associated with increases in adolescent heroin use and injection drug use: evidence from 44 US states
10.1016/j.drugpo.2023.103980 · doi-reference
Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis
10.1136/bmj.f174 · doi-reference
Principles of care for young adults with co-occurring psychiatric and substance use disorders
10.1542/peds.2020-023523f · doi-reference
SMART recovery for youth: a small, exploratory qualitative study examining the potential of a mutual-aid, peer support addictive behaviour change program for young people
10.1186/s13722-023-00379-w · doi-reference
“A peer support worker can really be there supporting the youth throughout the whole process”: a qualitative study exploring the role of peer support in providing substance use services to youth
10.1186/s12954-023-00853-3 · doi-reference
Community reinforcement and family training: an effective option to engage treatment-resistant substance-abusing individuals in treatment
10.1111/j.1360-0443.2010.03016.x · doi-reference
Management of opioid misuse and opioid use disorders among youth
10.1542/peds.2019-2056c · doi-reference
Treating adolescent opioid use disorder in primary care
10.1001/jamapediatrics.2023.6493 · doi-reference
Training in adolescent substance and opioid misuse in pediatric residency programs
10.1542/peds.2021-053423 · doi-reference
Explaining racial/ethnic differences in adolescent substance abuse treatment completion in the United States: a decomposition analysis
10.1016/j.jadohealth.2014.01.002 · doi-reference
Pediatricians’ role in overdose prevention: a call for universal naloxone dispensing
10.1542/peds.2024-067258 · doi-reference
Racial and ethnic disparities in mental health care for children and young adults: a national study
10.1177/0020731416662736 · doi-reference
Two new rating scales for opiate withdrawal
10.3109/00952998709001515 · doi-reference
The Clinical Opiate Withdrawal Scale (COWS)
10.1080/02791072.2003.10400007 · doi-reference
Medications for maintenance treatment of opioid use disorder in adolescents: a narrative review and assessment of clinical benefits and potential risks, offering a public health perspective-a commentary on Camenga et al
10.15288/jsad.2019.80.403 · doi-reference
Medication for adolescents and young adults with opioid use disorder
10.1016/j.jadohealth.2020.12.129 · doi-reference
Medication-assisted treatment of adolescents with opioid use disorders
10.1542/peds.2016-1893 · doi-reference
Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis
10.1001/jamapsychiatry.2021.0976 · doi-reference
Mortality during and following treatment with extended-release naltrexone based on data from two clinical trials
10.1016/j.drugalcdep.2025.112737 · doi-reference
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
10.1136/bmj.j1550 · doi-reference
10.17226/25310
10.17226/25310 · doi-reference
Recommended terminology for substance use disorders in the care of children, adolescents, young adults, and families
10.1542/peds.2022-057529 · doi-reference
